Kyntra BioLTS:0IL8 52 FCF Margin % is -371.51% as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 52/100 and a GF Value™ of $5.68 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 960 Biotechnology companies, Kyntra Bio ranks worse than 64.17% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kyntra Bio's Free Cash Flow for the
three
months ended in Mar. 2026 was $-13.89 Mil. Kyntra Bio's Revenue for the
three
months ended in Mar. 2026 was $3.74 Mil. Therefore, Kyntra Bio's FCF Margin % for the quarter that ended in Mar. 2026 was -371.51%.
The historical rank and industry rank for Kyntra Bio's FCF Margin % or its related term are showing as below:
LTS:0IL8'
s FCF Margin % Range Over the Past 10 Years
Min: -678.46 Med: -52.52 Max: 44.02
Current: -287.7
During the past 13 years, the highest FCF Margin % of Kyntra Bio was 44.02%. The lowest was -678.46%. And the median was -52.52%.
LTS:0IL8's FCF Margin % is ranked worse than 64.17% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs LTS:0IL8: -287.70
Kyntra Bio FCF Margin % Related Terms
Kyntra Bio FCF Margin % Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs SER, SNSE, PVCT: FCF Margin % Comparison
For the Biotechnology subindustry, Kyntra Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a FCF Margin % of -371.51% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #616 out of 960 companies in the Biotechnology industry, placing it in the top 64.2%.
Is Kyntra Bio's FCF Margin % too high?
Kyntra Bio's current FCF Margin % is -371.51%. Based on the distribution chart, Kyntra Bio ranks #616 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kyntra Bio has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's FCF Margin % compare to SER and SNSE?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #616 out of 960 companies for FCF Margin %. This places Kyntra Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current FCF Margin % is -371.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $6.86 — trading 20.7% above its estimated fair value. The current FCF Margin % is -371.51%. Kyntra Bio's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current FCF Margin % is -371.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $6.86 is trading 20.7% above its estimated GF Value™ of $5.68.
GuruFocus considers Kyntra Bio to be Modestly Overvalued.
Key valuation signals for LTS:0IL8:
FCF Margin %: -371.51%
GF Value™: $5.68 vs. price of $6.86 (20.7% above fair value)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
52GF Score
Get the complete analysis for LTS:0IL8
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
